Repository logo

Infoscience

  • English
  • French
Log In
Logo EPFL, École polytechnique fédérale de Lausanne

Infoscience

  • English
  • French
Log In
  1. Home
  2. Academic and Research Output
  3. Journal articles
  4. beta-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue
 
research article

beta-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue

Somm, Emmanuel
•
Henry, Hugues
•
Bruce, Stephen J.
Show more
2017
Jci Insight

beta-Klotho (encoded by Klb) is the obligate coreceptor mediating FGF21 and FGF15/19 signaling. Klb(-/-)mice are refractory to beneficial action of pharmacological FGF21 treatment including stimulation of glucose utilization and thermogenesis. Here, we investigated the energy homeostasis in Klb(-/-)mice on high-fat diet in order to better understand the consequences of abrogating both endogenous FGF15/19 and FGF21 signaling during caloric overload. Surprisingly, Klb(-/-)mice are resistant to diet-induced obesity (DIO) owing to enhanced energy expenditure and BAT activity. Klb(-/-)mice exhibited not only an increase but also a shift in bile acid (BA) composition featured by activation of the classical (neutral) BA synthesis pathway at the expense of the alternative (acidic) pathway. High hepatic production of cholic acid (CA) results in a large excess of microbiota-derived deoxycholic acid (DCA). DCA is specifically responsible for activating the TGR5 receptor that stimulates BAT thermogenic activity. In fact, combined gene deletion of Klb and Tgr5 or antibiotic treatment abrogating bacterial conversion of CA into DCA both abolish DIO resistance in Klb(-/-)mice. These results suggested that DIO resistance in Klb(-/-)mice is caused by high levels of DCA, signaling through the TGR5 receptor. These data also demonstrated that gut microbiota can regulate host thermogenesis via conversion of primary into secondary BA. Pharmacologic or nutritional approaches to selectively modulate BA composition may be a promising target for treating metabolic disorders.

  • Details
  • Metrics
Type
research article
DOI
10.1172/jci.insight.91809
Web of Science ID

WOS:000399843100009

Author(s)
Somm, Emmanuel
Henry, Hugues
Bruce, Stephen J.
Aeby, Sebastien
Rosikiewicz, Marta
Sykiotis, Gerasimos P.
Asrih, Mohammed
Jornayvaz, Francois R.
Denechaud, Pierre Damien
Albrecht, Urs
Show more
Date Issued

2017

Publisher

Amer Soc Clinical Investigation Inc

Published in
Jci Insight
Volume

2

Issue

8

Article Number

e91809

Editorial or Peer reviewed

REVIEWED

Written at

EPFL

EPFL units
UPSCHOONJANS  
Available on Infoscience
May 30, 2017
Use this identifier to reference this record
https://infoscience.epfl.ch/handle/20.500.14299/137952
Logo EPFL, École polytechnique fédérale de Lausanne
  • Contact
  • infoscience@epfl.ch

  • Follow us on Facebook
  • Follow us on Instagram
  • Follow us on LinkedIn
  • Follow us on X
  • Follow us on Youtube
AccessibilityLegal noticePrivacy policyCookie settingsEnd User AgreementGet helpFeedback

Infoscience is a service managed and provided by the Library and IT Services of EPFL. © EPFL, tous droits réservés